Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the best hot stocks to buy according to Wall Street analysts. In the middle of June, Citius Oncology, which is an oncology-focused subsidiary of Citius Pharmaceuticals, announced that it is nearing completion of preparations for the commercial launch of LYMPHIR. LYMPHIR is an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma/CTCL, indicated for Stage I-III disease after at least one prior systemic therapy.

The company anticipates a US launch of LYMPHIR in H2 2025. Citius Oncology has completed commercial-scale manufacturing of LYMPHIR, with sufficient packaged and labeled inventory to meet projected demand for 12 to 18 months post-launch. The product supports a shelf life of 60 months. To facilitate broad access and timely delivery across the US, Citius Oncology has executed one and is finalizing other distribution services agreements with multiple top-tier global pharmaceutical logistics partners.

Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR

An experienced physician performing a procedure using specialty pharmaceutical products.

The commercial team has developed a targeted launch strategy using a proprietary GenAI model to identify and engage key accounts. A suite of marketing and educational materials, such as clinical guides, dosing protocols, and disease awareness content, has been developed for providers, patients, and caregivers. LYMPHIR’s inclusion in the National Comprehensive Cancer Network/NCCN Clinical Practice Guidelines, along with the assignment of a permanent J-code under HCPCS and ongoing engagement with payors, positions the product for efficient reimbursement and coverage upon launch.

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is a biopharmaceutical company that develops and commercializes critical care products.

While we acknowledge the potential of CTXR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.